| Project/Area Number |
24500420
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Nerve anatomy/Neuropathology
|
|---|
| Research Institution | Tottori University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
KATO Masako 鳥取大学, 医学部, 助教 (80221183)
TAKIKAWA Miki 鳥取大学, 医学部, 助教 (80724369)
YOKOYAMA Atsushi 鳥取大学, 医学部, 助教 (90529447)
|
|---|
| Project Period (FY) |
2012-04-01 – 2015-03-31
|
| Project Status |
Completed (Fiscal Year 2014)
|
| Budget Amount *help |
¥5,330,000 (Direct Cost: ¥4,100,000、Indirect Cost: ¥1,230,000)
Fiscal Year 2014: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2013: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2012: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Keywords | 神経変性疾患 / 筋萎縮性側索硬化症 / 経口治療薬 / キサンチン酸化還元酵素 / キサンチン酸化還元酵素阻害剤 / プリン非類似体 / アロプリノール / プリン体 |
|---|
| Outline of Final Research Achievements |
The aim of this study is to develop the new therapeutic drug for amyotrophic lateral sclerosis (ALS) that is one of the intractable diseases in which there is not an effective therapy now. Non-purine analog xanthine oxidoreductase (XOR) inhibitors as the newly-developed therapeutic drug for ALS were administered orally into the ALS model mice. The results of this study were as follows: the treated ALS mice were significantly survived, and significantly improved ALS symptoms in comparison with the untreated ALS mice. Histopathologically, the treated ALS mice were well-preserved in motor neurons, compared with the untreated ALS mice. These results show that the non-purine analog XOR inhibitors are candidates for the human ALS therapeutic drug.
|
